Recombinant Cynomolgus BLAME/SLAMF8 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11100-BL

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11100-BL-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

XP_005541356.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all BLAME/SLAMF8 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey BLAME/SLAMF8 protein
Cynomolgus Monkey BLAME/SLAMF8
(Ala23-Asp233)
Accession # XP_005541356.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala23

Predicted Molecular Mass

50 kDa

SDS-PAGE

55-70 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera (Catalog #11100-BL) is immobilized at 1.0 µg/mL (100 µL/well), the concentration of Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera Biotinylated Protein that produces 50% of the optimal binding response is 0.200-2.00 μg/mL.

Scientific Data Images for Recombinant Cynomolgus BLAME/SLAMF8 Fc Chimera Protein, CF

Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera Protein Binding Activity.

When Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera Protein (Catalog # 11100-BL) is immobilized at 1.0 µg/mL (100 µL/well), the concentration of Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera Biotinylated Protein that produces 50% of the optimal binding response is 0.200-2.00 μg/mL.

Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Cynomolgus Monkey BLAME/SLAMF8 Fc Chimera Protein (Catalog # 11100-BL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-70 kDa and 110-140 kDa, respectively.

Formulation, Preparation and Storage

11100-BL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 200 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: BLAME/SLAMF8

B-lymphocyte activator macrophage expressed (BLAME), also known as SLAMF8, is a type I transmembrane protein that belongs to the CD2 subset of immunoglobulin superfamily cell receptors. The SLAM family is comprised of nine surface receptors, expressed mainly on hematopoietic cells, and they have been shown to function as adhesion molecules and modulators of immune responses (1). BLAME, along with SLAMF2 and SLAMF9, are considered atypical SLAM family members due to the low homology in their cytoplasmic domains compared to the rest of the SLAM family (2). Mature cynomologus BLAME consists of an extracellular domain (ECD) with an IgV and an IgC2 domain, a transmembrane segment, and a short cytoplasmic domain. Within the ECD, cynomologus BLAME shares 96% amino acid sequence identity with human BLAME. BLAME is expressed by various myeloid cells, such as neutrophils, macrophages, and dendritic cells (3). BLAME suppresses macrophage function but enhances the growth of neoplastic mast cells via SHP-2 (4). BLAME negatively regulates the activity of PKC-delta, which phosphorylates the p40phox subunit of the NOX2 complex (5). BLAME is abundantly expressed in T cells in pediatric cancers and Epstein-Barr virus-positive gastric cancers and is a potential immunotherapy target for several diseases (6-8). Higher SLAMF8 expression may predict better anti-PD1 immunotherapy efficacy in GI cancer (9).

References

  1. Shachar, I. et al. (2019) Clin. Immunol. 204:23.
  2. Dragovich, M.A. and Mor, A. (2018) Autoimmunity reviews, 17:674.
  3. Wang, G. et al. (2015) PloS one, 10:e0121968.
  4. Sugimoto, A. et al. (2018) Exp. Dermatol. 27:641.
  5. Wang, G. et al. (2012) J. Immunol. 188:5829.
  6. Orentas, R.J. et al. (2012) Front Oncol. 2:194.
  7. Sugimoto, A. et al. (2020) Sci. Rep. 10:2505.
  8. Zhang, Q. et al. (2019) J. Clin. Oncol. 37:e14078.
  9. Zhang Q. et al. (2021) Clin. Transl. Immunology. 10:1347.

Long Name

SLAM Family Member 8

Alternate Names

CD353, SBBI42, SLAMF8

Entrez Gene IDs

56833 (Human); 74748 (Mouse); 289237 (Rat); 102122568 (Cynomolgus Monkey)

Gene Symbol

SLAMF8

UniProt

XP_005541356.1

Additional BLAME/SLAMF8 Products

Product Documents for Recombinant Cynomolgus BLAME/SLAMF8 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Cynomolgus BLAME/SLAMF8 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.